Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q92187

UPID:
SIA8D_HUMAN

ALTERNATIVE NAMES:
Alpha-2,8-sialyltransferase 8D; Polysialyltransferase-1; Sialyltransferase 8D; Sialyltransferase St8Sia IV

ALTERNATIVE UPACC:
Q92187; A8KA07; G3V104; Q8N1F4; Q92693

BACKGROUND:
The enzyme CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase, known alternatively as Polysialyltransferase-1 or Sialyltransferase St8Sia IV, catalyzes critical reactions for neural cell development. By facilitating the synthesis of polysialic acid on N-CAM, it supports neural cell plasticity, an essential feature for brain development and cognitive functions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase offers a pathway to novel therapeutic approaches. Given its central role in neural development, targeting this enzyme could lead to breakthroughs in treating neurological conditions by promoting neural plasticity and repair.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.